Diabetes Metab J.  2024 Jan;48(1):112-121. 10.4093/dmj.2022.0402.

Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus

• Han JH
• Joung KH
• Lee JC
• Kim OS
• Choung S
• Kim JM
• Kang YE
• Yi HS
• Lee JH
• Ku BJ
• Kim HJ

• KMID: 2551267
• DOI: http://doi.org/10.4093/dmj.2022.0402

Abstract

Background
Type 2 diabetes mellitus (T2DM) induces endothelial dysfunction and inflammation, which are the main factors for atherosclerosis and cardiovascular disease. The present study aimed to compare the effects of rosuvastatin monotherapy and rosuvastatin/ezetimibe combination therapy on lipid profile, insulin sensitivity, and vascular inflammatory response in patients with T2DM.
Methods
A total of 101 patients with T2DM and dyslipidemia were randomized to either rosuvastatin monotherapy (5 mg/day, n=47) or rosuvastatin/ezetimibe combination therapy (5 mg/10 mg/day, n=45) and treated for 12 weeks. Serum lipids, glucose, insulin, soluble intercellular adhesion molecule-1 (sICAM-1), and peroxiredoxin 4 (PRDX4) levels were determined before and after 12 weeks of treatment.
Results
The reduction in low density lipoprotein cholesterol (LDL-C) by more than 50% from baseline after treatment was more in the combination therapy group. The serum sICAM-1 levels increased significantly in both groups, but there was no difference between the two groups. The significant changes in homeostasis model assessment of insulin resistance (HOMA-IR) and PRDX4 were confirmed only in the subgroup in which LDL-C was reduced by 50% or more in the combination therapy group. However, after adjusting for diabetes mellitus duration and hypertension, the changes in HOMA-IR and PRDX4 were not significant between the two groups.
Conclusion
Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin monotherapy, it had no additional effects on insulin sensitivity and vascular inflammatory response. Further studies are needed on the effect of long-term treatment with ezetimibe on insulin sensitivity and vascular inflammatory response.

Keyword

Diabetes mellitus, type 2; Ezetimibe; Inflammation; Insulin resistance; Rosuvastatin calcium

Figure

• 

  Fig. 1. Change in homeostasis model assessment of insulin resistance (HOMA-IR) levels in subgroups divided by the degree of low density lipoprotein cholesterol (LDL-C) reduction after treatment in the (A) rosuvastatin group and (B) rosuvastatin/ezetimibe group. NS, not significant.

• 

  Fig. 2. Change in peroxiredoxin 4 (PRDX4) levels in subgroup divided by the degree of low density lipoprotein cholesterol (LDL-C) reduction after treatment in the (A) rosuvastatin group and (B) rosuvastatin/ezetimibe group.

• 

Reference

1. Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus and inflammation. Curr Diab Rep. 2013; 13:435–44.

2. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005; 115:1111–9.

3. Yun JS, Ko SH, Kim JH, Moon KW, Park YM, Yoo KD, et al. Diabetic retinopathy and endothelial dysfunction in patients with type 2 diabetes mellitus. Diabetes Metab J. 2013; 37:262–9.

4. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord. 2010; 11:61–74.

5. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25 Pt B):2889–934.

6. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 Guidelines for the management of dyslipidemia in Korea. J Lipid Atheroscler. 2019; 8:78–131.

7. Hong N, Lee YH, Tsujita K, Gonzalez JA, Kramer CM, Kovarnik T, et al. Comparison of the effects of ezetimibe-statin combination therapy on major adverse cardiovascular events in patients with and without diabetes: a meta-analysis. Endocrinol Metab (Seoul). 2018; 33:219–27.

8. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372:2387–97.

9. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009; 32:1924–9.

10. Kater AL, Batista MC, Ferreira SR. Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects. Diabetol Metab Syndr. 2010; 2:34.

11. Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014; Oct. 88:3–11.

12. Wilson PW, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT. Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019; 139:e1144–61.

13. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005; 1:183–98.

14. Favero G, Paganelli C, Buffoli B, Rodella LF, Rezzani R. Endothelium and its alterations in cardiovascular diseases: life style intervention. Biomed Res Int. 2014; 2014:801896.

15. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006; 113:1708–14.

16. Strey CH, Young JM, Lainchbury JH, Frampton CM, Nicholls MG, Richards AM, et al. Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart. 2006; 92:1603–9.

17. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005; 111:2356–63.

18. Chia PY, Teo A, Yeo TW. Overview of the assessment of endothelial function in humans. Front Med (Lausanne). 2020; 7:542567.

19. Sena CM, Pereira AM, Seica R. Endothelial dysfunction: a major mediator of diabetic vascular disease. Biochim Biophys Acta. 2013; 1832:2216–31.

20. Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, et al. Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality. J Am Heart Assoc. 2012; 1:e002956.

21. El Eter E, Al Masri A, Habib S, Al Zamil H, Al Hersi A, Al Hussein F, et al. Novel links among peroxiredoxins, endothelial dysfunction, and severity of atherosclerosis in type 2 diabetic patients with peripheral atherosclerotic disease. Cell Stress Chaperones. 2014; 19:173–81.

22. Guo X, Yamada S, Tanimoto A, Ding Y, Wang KY, Shimajiri S, et al. Overexpression of peroxiredoxin 4 attenuates atherosclerosis in apolipoprotein E knockout mice. Antioxid Redox Signal. 2012; 17:1362–75.

23. Abbasi A, Corpeleijn E, Gansevoort RT, Gans RO, Struck J, Schulte J, et al. Circulating peroxiredoxin 4 and type 2 diabetes risk: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia. 2014; 57:1842–9.

24. Al-Masri AA, El Eter E, Tayel S, Zamil H. Differential associations of circulating peroxiredoxins levels with indicators of glycemic control in type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2014; 18:710–6.

25. Ding Y, Yamada S, Wang KY, Shimajiri S, Guo X, Tanimoto A, et al. Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice. Antioxid Redox Signal. 2010; 13:1477–90.

26. Nabeshima A, Yamada S, Guo X, Tanimoto A, Wang KY, Shimajiri S, et al. Peroxiredoxin 4 protects against nonalcoholic steatohepatitis and type 2 diabetes in a nongenetic mouse model. Antioxid Redox Signal. 2013; 19:1983–98.

27. Vivoli A, Ghislain J, Filali-Mouhim A, Angeles ZE, Castell AL, Sladek R, et al. Single-cell RNA sequencing reveals a role for reactive oxygen species and peroxiredoxins in fatty acid-induced rat b-cell proliferation. Diabetes. 2023; 72:45–58.

28. Gross MD, Bielinski SJ, Suarez-Lopez JR, Reiner AP, Bailey K, Thyagarajan B, et al. Circulating soluble intercellular adhesion molecule 1 and subclinical atherosclerosis: the Coronary Artery Risk Development in Young Adults Study. Clin Chem. 2012; 58:411–20.

29. Luc G, Arveiler D, Evans A, Amouyel P, Ferrieres J, Bard JM, et al. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis. 2003; 170:169–76.

30. Zonneveld R, Martinelli R, Shapiro NI, Kuijpers TW, Plotz FB, Carman CV. Soluble adhesion molecules as markers for sepsis and the potential pathophysiological discrepancy in neonates, children and adults. Crit Care. 2014; 18:204.

31. Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep. 2009; 61:22–32.

32. Gho YS, Kleinman HK, Sosne G. Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res. 1999; 59:5128–32.

33. Kevil CG, Orr AW, Langston W, Mickett K, Murphy-Ullrich J, Patel RP, et al. Intercellular adhesion molecule-1 (ICAM-1) regulates endothelial cell motility through a nitric oxide-dependent pathway. J Biol Chem. 2004; 279:19230–8.

34. Rieckmann P, Michel U, Albrecht M, Bruck W, Wockel L, Felgenhauer K. Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J Neuroimmunol. 1995; 60:9–15.

35. Kim JY, Kim DH, Kim JH, Lee D, Jeon HB, Kwon SJ, et al. Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-b plaques. Cell Death Differ. 2012; 19:680–91.

36. Omi H, Okayama N, Shimizu M, Fukutomi T, Imaeda K, Okouchi M, et al. Statins inhibit high glucose-mediated neutrophil-endothelial cell adhesion through decreasing surface expression of endothelial adhesion molecules by stimulating production of endothelial nitric oxide. Microvasc Res. 2003; 65:118–24.

37. Chung HK, Lee IK, Kang H, Suh JM, Kim H, Park KC, et al. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med. 2002; 34:451–61.

38. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J. 2007; 153:881–8.

39. Sadeghi MM, Collinge M, Pardi R, Bender JR. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J Immunol. 2000; 165:2712–8.

40. Bernot D, Benoliel AM, Peiretti F, Lopez S, Bonardo B, Bongrand P, et al. Effect of atorvastatin on adhesive phenotype of human endothelial cells activated by tumor necrosis factor alpha. J Cardiovasc Pharmacol. 2003; 41:316–24.

41. Sun C, Zheng W, Liang L, Liu Z, Sun W, Tang R. Ezetimibe improves rosuvastatin effects on inflammation and vascular endothelial function in acute coronary syndrome patients undergoing PCI. J Interv Cardiol. 2021; 2021:2995602.

42. Krysiak R, Zmuda W, Okopien B. The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med. 2012; 271:32–42.

43. Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol. 2018; 15:757–69.

44. Macedo AF, Douglas I, Smeeth L, Forbes H, Ebrahim S. Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink. BMC Cardiovasc Disord. 2014; 14:85.

45. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305:2556–64.

46. Kain V, Kapadia B, Misra P, Saxena U. Simvastatin may induce insulin resistance through a novel fatty acid mediated cholesterol independent mechanism. Sci Rep. 2015; 5:13823.

47. Adachi H, Nakano H, Yamamoto K, Nakata M, Bekki H, Honma T, et al. Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia. Lipids Health Dis. 2015; 14:1.

48. Cho Y, Kim RH, Park H, Wang HJ, Lee H, Kang ES. Effect of ezetimibe on glucose metabolism and inflammatory markers in adipose tissue. Biomedicines. 2020; 8:512.